Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome

AI Insight

Etuvetidigene autotemcel is a gene therapy for Wiskott-Aldrich syndrome, a rare X-linked primary immunodeficiency caused by mutations in the WAS gene. The treatment involves ex vivo lentiviral gene therapy using autologous hematopoietic stem cells transduced with a functional WAS gene. Clinical trial data demonstrated successful restoration of WAS protein expression, improvement in immune function, and reduction in disease-related complications including infections, bleeding, and eczema in treated patients.

Why it matters

This represents a potentially curative treatment for a severe inherited immunodeficiency that previously required allogeneic stem cell transplantation with its associated risks. The gene therapy approach offers an alternative for patients lacking matched donors and may eliminate lifelong immunosuppression and disease-related complications.